title: Comparison of different classes of CpG-ODN in augmenting the generation of human epitope peptide-specific CTLs.
abstract: Three distinct classes of CpG-oligonucleotides (ODN) (CpG-A, CpG-B and CpG-C) have been identified on the basis of differences in their structures and immune effects. To date, only CpG-B is applied for clinical treatments; however, it is still unknown which of the different CpG-ODN classes is most useful as an adjuvant for human cancer vaccine therapy. In the present study, we examined the activity of these 3 types of CpG-ODN in enhancing the induction of human peptide-specific CTLs. Our data showed that the specific cytotoxicity was augmented in the presence of CpG-A, -B and -C but not in the presence of control ODN, and the augmenting effect was most potent with CpG-A. Flow cytometric analysis showed the subpopulation of effector-memory cells in CD8+ cells was most increased with CpG-A. Furthermore, depletion of PDCs from PBMCs before stimulation with peptide and CpG-ODN completely abrogated the augmenting effect of CpG-ODN. These data indicated that the stimulation of PDCs by CpG-ODN augmented the generation of peptide-specific CTLs, and CpG-A was superior to CpG-B and CpG-C in terms of augmenting the generation of human peptide-specific CTLs in vitro.
authors.affiliation: Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Katsuda
authors.forename: Makoto
authors.initials: M
authors.lastname: Iwahashi
authors.forename: Kenji
authors.initials: K
authors.lastname: Matsuda
authors.forename: Motoki
authors.initials: M
authors.lastname: Miyazawa
authors.forename: Mikihito
authors.initials: M
authors.lastname: Nakamori
authors.forename: Masaki
authors.initials: M
authors.lastname: Nakamura
authors.forename: Toshiyasu
authors.initials: T
authors.lastname: Ojima
authors.forename: Takeshi
authors.initials: T
authors.lastname: Iida
authors.forename: Keiji
authors.initials: K
authors.lastname: Hayata
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yamaue
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000276:immunology*; D002460:Cell Line; D003713:Dendritic Cells / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D015488:HIV Antigens / Q000276:immunology; D006801:Humans; D016898:Interferon-alpha / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000276:immunology; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D010455:Peptides / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D015295:Antigens, Tumor-Associated, Carbohydrate; C408982:CPG-oligonucleotide; D018984:Epitopes, T-Lymphocyte; D015488:HIV Antigens; D016898:Interferon-alpha; D009838:Oligodeoxyribonucleotides; D010455:Peptides